ArticleJournal of thoracic disease2024

Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study.

Pan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.